论文部分内容阅读
目的探讨复查PET/CT标准摄取值(SUL)评估非小细胞肺癌(NSCLC)不同周期化疗后疗效的价值。方法 NSCLC患者53例,参照PERCIST标准确定靶病灶。化疗2周期后复查的患者30例(A组),化疗4-6周期后复查的患者23例(B组),两组病例各30个靶病灶。以SUL下降50%作为B组靶病灶部分缓解(PMR)的阈值,比较两组靶病灶治疗前后SUL的变化及治疗有效率。结果 B组靶病灶SUL下降百分比高于A组[(50.00±26.96)%vs.(32.00±42.00)%](P<0.05)。B组靶病灶治疗有效率高于A组(80.0%vs.46.7%)(P<0.05);B组复查的靶病灶以SUL下降50%作为PMR标准,两组治疗效果差异无统计学意义(P>0.05)。结论 NSCLC患者应用PERCIST标准评价疗效时,化疗2周期复查时SUL下降30%以上的疗效类似于4-6周期复查时SUL下降50%以上的疗效。
Objective To investigate the value of retesting the standard value of PET / CT (SUL) in assessing the efficacy of chemotherapy after different cycles of non-small cell lung cancer (NSCLC). Methods NSCLC patients 53 cases, with reference to PERCIST criteria to determine the target lesion. Thirty patients (group A) were examined after 2 cycles of chemotherapy, 23 patients were examined after 4-6 cycles of chemotherapy (group B), and each group had 30 target lesions. SUL decreased by 50% as the target group B partial remission (PMR) threshold, compared two groups of target lesions before and after treatment of SUL changes and treatment efficiency. Results The percentage of SUL in group B was higher than that in group A [(50.00 ± 26.96)% vs (32.00 ± 42.00)%] (P <0.05). The effective rate of target lesion in group B was higher than that in group A (80.0% vs.46.7%) (P <0.05). The target lesion in group B was reduced by 50% of SUL as PMR standard. There was no significant difference between the two groups P> 0.05). Conclusions When using PERCIST criteria to evaluate the efficacy of NSCLC, the effect of reducing the SUL by more than 30% during 2 cycles of chemotherapy is similar to that of reducing the SUL by more than 50% during the 4-6 cycles.